Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 14/20 | 0.51 |
| ▸ | TLR2 | O60603 | 1/20 | 0.51 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.51 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.51 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7273581 | 0.87 | ERN1 (0.51) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL1654624 | 0.87 | ERN1 (0.54) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL6213995 | 0.82 | ALDH1A1 (0.43) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL3881769 | 0.81 | CYSLTR2 (0.46) | CYSLTR2CYSLTR1 | |
| SCHEMBL3881959 | 0.80 | CYSLTR2 (0.43) | ERN1TLR2TLR1TLR6CYSLTR2 | |
| SCHEMBL5517444 | 0.79 | MEN1 (0.53) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL3333141 | 0.79 | ERN1 (0.50) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL7272620 | 0.79 | ALOX5 (0.43) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL10959657 | 0.79 | ERN1 (0.48) | ERN1CYSLTR2CYSLTR1L3MBTL1 | |
| SCHEMBL6232353 | 0.78 | CETP (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144729-A1 | COUMARIN DERIVATIVES | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| US-20090318546-A1 | Chromen-2-One Derivatives | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | disclosed |
| EP-2109606-A1 | CHROMENE S1P1 RECEPTOR ANTAGONIST | Novartis Ag (CH) | 2009-10-21 | — | — | EP | disclosed |
| EP-2010511-A1 | CHROMEN-2-ONE DERIVATIVES | Novartis AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008092930-A1 | CHROMENE S1P1 RECEPTOR ANTAGONIST | NOVARTIS AG (CH) | 2008-08-07 | — | — | WO | disclosed |
| WO-2007115820-A1 | CHROMEN-2-ONE DERIVATIVES | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318546-A1 | Chromen-2-One Derivatives | CYP1A2, CYP4B1, CYP1B1 | ERN1 1633/4885TLR2 3287/4885TLR1 3515/4885 |
| US-20100144729-A1 | COUMARIN DERIVATIVES | F3, CYP3A7, CYP3A4 | ERN1 908/4885TLR2 2753/4885TLR1 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.